[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AVEO Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100521075","phase-3-a-study-of-ficlatuzumab-in-combination-with-cetuximab-in-participants-with-recurrent-or-metastatic-rm-hpv-negative-head-and-neck-squamous-cell-carcinoma-100521075",false,"NCT06064877","A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R\u002FM) HPV Negative Head and Neck Squamous Cell Carcinoma","A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R\u002FM) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)","FIERCE-HN","Inclusion Criteria:\n\n* Male or female and ≥ 18 years of age\n* Histologically and\u002For cytologically confirmed primary diagnosis of R\u002FM HNSCC\n* Participants with oropharyngeal cancer will be required to have proof of p16 negative status submitted on the basis of a pathology report\n* At least 1 measurable lesion by contrast CT or MRI scan according to RECIST v.1.1. Such lesions must not have been previously irradiated; if the measurable lesion(s) has been irradiated, clear progression must be documented\n* Participants must have failed prior therapy with an anti-PD-1\u002FPD-L1 ICI and with platinum-based chemotherapy administered in combination or sequentially, in either the locally advanced or R\u002FM setting. Failure of prior treatment may be due to progression of disease or intolerance to treatment\n* Patient's tumor must be considered inoperable and incurable\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with a life expectancy of at least 12 weeks\n* For women of childbearing potential (WOCBP), documentation of negative serum pregnancy test within 30 days of randomization\n* For WOCBP and male participants whose sexual partners are of childbearing potential, agreement to use an effective method of contraception during the study and for at least 5 months after the last dose of study treatment. Birth control methods which may be considered highly effective include methods that achieve a failure rate of less than 1% per year when used consistently and correctly.\n* Ability to give written informed consent and comply with protocol requirements\n* Patients with feeding tubes are eligible for the study.\n* Archived tissue sample must be submitted to the Sponsor-designated laboratory within 60 days of randomization for c-Met analysis (if a tissue sample is not available, a fresh biopsy may be required prior to enrollment)\n\nExclusion Criteria:\n\n* Participants who have received \\> 2 prior lines of anticancer therapy or prior treatment with cetuximab\u002Falternative EGFR inhibitors for the treatment of R\u002FM HNSCC\n* History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent or cetuximab\n* Known or suspected untreated and uncontrolled brain metastases or leptomeningeal carcinomatosis Note: Participants with locally treated brain metastases are eligible provided 2 weeks have elapsed since local therapy. Participants are allowed to continue steroid taper during the start of study treatment.\n* Prior treatment with any other investigational drug or biologic agent or radiation therapy before a washout has been completed (must be completed prior to randomization):\n\n  1. 2 weeks (14 days) or 5 half-lives, whichever is shorter, for chemotherapeutic agents, small molecules, and checkpoint inhibitors\n  2. 3 weeks (21 days) or 5 half-lives, whichever is shorter, for antibody-drug conjugates\n  3. 4 weeks (28 days) for cell therapies\n  4. 2 weeks (14 days) for radiation therapy\n* Any unresolved and significant toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events \\[NCI-CTCAE\\] version 5.0) Grade 2 or greater from previous anticancer therapy (including radiation therapy), other than alopecia\n* Significant cardiovascular disease, including: Cardiac failure New York Heart Association class III or IV; Myocardial infarction, severe or unstable angina within 6 months prior to randomization; History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)\n* Any other medical condition or psychiatric condition that, in the opinion of the Investigator, might interfere with the participant's involvement in the study or interfere with the interpretation of study results\n* History of prior malignancy within 2 years prior to randomization (except for adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or cervix, superficial bladder cancer, or early-stage prostate cancer, without evidence of recurrence; participants may or may not be on maintenance therapy)\n* Participants who are positive for hepatitis B virus (HBV) or hepatitis C virus (HCV) with indication of acute or chronic hepatitis (as defined in protocol)\n* Radiographic evidence (historical or at screening) of interstitial lung disease or idiopathic pulmonary fibrosis\n* Female participants who are pregnant or breastfeeding\n\nA full list of inclusion and exclusion criteria can be found in the protocol.","ALL","18 Years",{"count":20,"type":21},410,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent\u002Fmetastatic (R\u002FM) HPV-negative Head and Neck Cancer.\n\nThe primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and\u002For overall survival.",[27,28],"Metastatic Head-and-neck Squamous-cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma",[30,31,32,33,34],"Recurrent","Metastatic","HPV-negative","Head and Neck","Squamous Cell Carcinoma","RECRUITING","2026-04-06",{"date":38,"type":39},"2026-04-09","ACTUAL",{"date":41,"type":39},"2024-01-11",{"date":43,"type":21},"2027-11",{"name":45,"class":46},"AVEO Pharmaceuticals, Inc.","INDUSTRY",112,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100505757","phase-1-a-dose-escalation-study-of-av-380-in-cancer-patients-with-cachexia-100505757","NCT05865535","A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia","A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels","Inclusion Criteria:\n\n1. Patient must be ≥ 18 years of age at the time of signing the informed consent.\n2. Patients with histologically confirmed solid tumor cancer who are actively receiving SoC therapy for this cancer.\n3. Patients with cachexia as defined by Fearon criteria:\n\n   1. Weight loss \\> 5% over past 6 months (in absence of simple starvation), or\n   2. BMI \\\u003C 20 kg\u002Fm2 and any degree of weight loss \\> 2%, or\n   3. Sarcopenia and any degree of weight loss \\> 2%\n4. Patients with life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n1. History of allergic or anaphylactic reaction to any monoclonal antibody (IgG protein) or molecules made of components of monoclonal antibody\n2. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 2 weeks before first dose of study treatment.\n3. Myocardial infarction or heart failure of New York Heart Association Grade 3-4 within 3 months prior to start of protocol therapy\n4. Uncontrolled pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\n5. Cachexia is caused by other reasons (e.g., severe chronic obstructive pulmonary disease, heart failure, or HIV\u002FAIDS), or the patient has uncontrolled reversible causes of reduced oral food intake, including, but not limited to, oral mucositis, nausea\u002Fvomiting, diarrhea, and\u002For obstruction, impairing the patient's ability to eat as determined by the Investigator.\n6. Patients receiving tube feedings or parenteral nutrition at the time of Screening.",{"count":56,"type":21},30,[58],"PHASE1","This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.",[61],"Cachexia","2026-01-07",{"date":64,"type":39},"2026-01-08",{"date":66,"type":39},"2023-06-13",{"date":68,"type":21},"2026-12-31",{"name":45,"class":46},12,""]